NCR3 and lymphoma: To address this lack of knowledge, our group previously published that the infusion of autograft inhibitory killer immunoglobulin-like receptor (KIR) 2DL2 and activating NKp30 NK cell receptors were predictors of clinical outcomes in lymphoma patients undergoing APBHSCT [8].